COPD Drug Pipeline: Biologics & Repair — PatSnap Eureka
COPD Drug Pipeline: Antiviral Triggers, Bronchodilator Biologics, and Epithelial Repair
The COPD innovation landscape is shifting from bronchodilation alone toward biologic cytokine blockade, viral-trigger attenuation, and alveolar repair. Explore key molecular targets, leading assignees, and clinical signals across the 2007–2025 patent dataset.
A Heterogeneous Syndrome With Multiple Druggable Axes
COPD is characterized by persistent airflow limitation (post-bronchodilator FEV1/FVC < 0.70), airway and alveolar abnormalities, and chronic inflammatory immune responses to noxious particles or gases. According to the World Health Organization, COPD remains one of the leading causes of global morbidity and mortality.
The dominant molecular targets identified in this patent and literature dataset are cytokines and their receptors—particularly the IL-33/ST2 axis, the IL-4/IL-13 shared receptor IL-4R, IL-5 receptor alpha (IL-5Rα), and IL-1R1—alongside structural and enzymatic targets including phosphodiesterase 4 (PDE4), muscarinic M3 receptors, matrix metalloproteinases (MMPs), and the chemokine receptor CXCR2.
Approximately 30% of COPD patients have elevated airway eosinophils, making eosinophilic inflammation a major stratification and therapeutic target. IL-33 expression is reported to be elevated in COPD and inversely correlated with lung function, according to filings from MedImmune Limited, which note that neutralization of IL-33 activity by MEDI3506 has potential to disrupt inflammatory structural damage cycles in COPD lungs.
The ST2 axis (IL-33 receptor) is specifically described as modulating viral-triggered inflammatory cascades. Retrieved data from Genentech indicate that ST2- or IL-33-deficient mice showed reduced inflammatory responses to respiratory viral infection without impairing antiviral host defense — a critical distinction for the antiviral trigger dimension of COPD management.
Biomarker-linked molecular targets DMBT1, KIAA1199, and TMSB15A — among a panel of over 30 genes — are identified in multiple filings from Transgenion GmbH as markers of progressive, irreversible lung damage, providing diagnostic stratification of COPD subtypes including stable and progressive disease.
COPD Patent Filing Trends & Target Landscape
Key quantitative signals extracted from the COPD patent and literature dataset (2007–2025), illustrating the acceleration of biologic programs and the relative density of molecular target activity.
COPD Patent Filing Activity by Period (2007–2025)
Filing activity accelerates sharply from 2019 onward, driven by IL-33 and IL-4R biologic programs from Regeneron, MedImmune, and AstraZeneca.
Molecular Target Representation in COPD Patent Dataset
IL-33/ST2 and IL-4R dominate filing density; PDE4 and IL-5Rα show medium activity; CXCR2 and MMP remain early-stage.
Biologic Antagonists Targeting Cytokine Axes
Monoclonal antibody-based blockade of epithelial-derived cytokine alarmins and their receptors dominates the COPD patent landscape, with active commercial IP build-out across multiple jurisdictions from 2019–2025.
Anti-IL-33 Antibodies: Tozorakimab & Regeneron/Sanofi Programs
Regeneron Pharmaceuticals and Sanofi Biotechnology filed extensively across WO, US, AU, BR, TW, NZ, JP, and KR jurisdictions for anti-IL-33 antibodies covering treatment and prevention of COPD and reduction of acute exacerbation of COPD (AECOPD) events. MedImmune Limited (an AstraZeneca subsidiary) independently filed for MEDI3506 (tozorakimab) in specific dosing regimens (300–600 mg at Q4W or Q8W intervals). One retrieved filing references an ongoing Phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating tozorakimab in COPD patients with exacerbation history (NCT05166889).
Phase III signal · NCT05166889Genentech ST2 Antagonist: Attenuating Virus-Induced Cascades
Genentech filed for ST2 (IL-33 receptor) antagonism specifically for reducing annualized exacerbation rates by up to 45% vs. standard of care. Retrieved data explicitly link ST2 pathway inhibition to attenuating virus-induced inflammatory cascades in COPD without impairing antiviral host defense. A Phase IIb, randomized, double-blind, placebo-controlled, multicenter study enrolling approximately 930 COPD patients (current or ex-smokers with frequent exacerbations) is described, stratified by smoking status and region.
Phase IIb · ~930 patientsAnti-IL-4R (Dupilumab-Class): Dual IL-4/IL-13 Blockade in COPD
Regeneron Pharmaceuticals and Sanofi Biotechnology co-filed multiple IL-4R antagonist patents (2024–2025) across WO, US, AU, IL, TW, and KR. These claims target COPD patients via blocking the shared IL-4/IL-13 receptor, leveraging the type 2 inflammatory mechanism validated in asthma. Priority dates trace to early 2023 provisional applications, indicating rapid translation from the asthma indication. COPD patients with elevated eosinophils and elevated periostin are the proposed responder endotype.
2023 priority date · Rapid asthma translationBenralizumab (AstraZeneca): Biomarker-Enriched Patient Selection
AstraZeneca filed multiple patents for benralizumab (afucosylated anti-IL-5Rα antibody) in COPD across JP jurisdictions (2016–2025), specifically targeting eosinophil-high patient subpopulations (blood eosinophil count ≥300/µL), patients with ≥2 prior exacerbations per year, and those already on triple background therapy (ICS + LABA + LAMA). This represents a precision medicine approach using biomarker-enriched populations — the most specific enrollment criteria in this dataset.
≥300 eos/µL · Triple background therapyAnti-TSLP Antibody (MedImmune LLC): Extending the Alarmin Paradigm
A single retrieved filing from MedImmune LLC covers the use of an anti-thymic stromal lymphopoietin (TSLP) antibody for COPD treatment, extending the alarmin-blocking paradigm to the TSLP node. This filing (TW, 2025) signals that the alarmin axis in COPD is being approached from multiple upstream entry points, complementing the IL-33/ST2 programs.
TSLP node · Alarmin paradigm extensionIL-1 Pathway & B-Cell Depletion: Earlier-Stage Biologics
MedImmune Limited filed for anti-IL-1R1 and anti-IL-1α antibodies specifically targeting COPD exacerbations (2011–2013), proposing that IL-1 pathway blockade reduces airway inflammation during acute episodes. Genmab A/S filed for CD20-binding molecules in COPD (2007–2014), proposing B-cell depletion to reduce airway inflammation measured by IL-4, IL-6, IL-8, TNF-α, and GRO-α. No recent filings for CD20 in COPD were retrieved, suggesting limited program advancement.
IL-1R1 (2011–2013) · CD20 limited progressionSmall-Molecule Bronchodilators and Anti-Inflammatory Agents
Multiple retrieved patents describe small-molecule approaches targeting airway tone and pulmonary inflammation. PDE4 inhibitors are the most represented small-molecule class, with filings from Pfizer Products Inc. (nicotinamide derivatives), GlaxoSmithKline (quinoline derivatives), Gilead Sciences (bifunctional quinoline derivatives combining PDE4 inhibition with bronchodilation), and Chiesi Farmaceutici (dual PDE4/M3 antagonist aminoester derivatives). PDE4 inhibition elevates intracellular cAMP, reducing degranulation of eosinophils and neutrophils, suppressing TNF-α and IL-8, and relaxing airway smooth muscle.
Boehringer Ingelheim Pharma filed for inhaled combinations of a PDE4 inhibitor and tiotropium (a long-acting muscarinic antagonist, LAMA) to address both bronchodilation and inflammation simultaneously. This combination approach formalizes the concept that bronchodilator and anti-inflammatory mechanisms can be co-delivered in a single inhaled product.
A retrieved academic paper describes the 2013 regulatory approvals of two novel fixed-combination inhalers: fluticasone furoate + vilanterol (ICS + LABA; GlaxoSmithKline/Theravance) and indacaterol + glycopyrronium (LABA + LAMA; Novartis, marketed as Ultibro), described as a major step in COPD pharmacotherapy. According to the European Medicines Agency, fixed-dose combination inhalers remain foundational in COPD maintenance therapy.
Mereo BioPharma 1 Limited filed for a p38 MAPK inhibitor specifically for AECOPD treatment and prevention, targeting overproduction of IL-1, IL-6, IL-8, and TNF-α. ReversPAH LLC filed for inhaled prostacyclin analogues (beraprost or iloprost) combined with diethylcarbamazine or zileuton, specifically positioned for steroid-unresponsive COPD components including pulmonary hypertension and eosinophilia.
According to the GOLD COPD guidelines, pharmacological therapy should be guided by symptom burden and exacerbation risk — a framework that supports the precision-medicine stratification approaches observed across these filings. Learn more about small-molecule drug discovery approaches in PatSnap's platform.
Epithelial Repair, Epigenetic & Structural Remodeling Approaches
Emerging approaches address the root structural damage in COPD — alveolar regeneration, oxidative stress, epigenetic dysregulation, and immune tolerance — going beyond symptom management toward disease modification.
Epigenetic Co-Delivery Systems (Tokyo Metropolitan University)
Liposome/biodegradable polymer carriers capable of simultaneously co-delivering antioxidants (to address reactive oxygen species [ROS]-mediated oxidative damage) and plasmid DNA encoding epigenetic regulatory enzymes. This approach addresses the dual COPD pathogenic mechanisms of oxidative damage and epigenetic dysregulation simultaneously. Filed in JP (2016 and 2020).
Curcuminoid Compositions for Alveolar Regeneration (Sami-Sabinsa Group)
A CN patent for a composition enriched in bisdemethoxycurcumin (≥20% w/w) with demethoxycurcumin and curcumin, specifically described for regenerating damaged alveolar cells in emphysema and COPD, including COPD arising from viral infection (COVID-19). This signals a natural product-derived approach to structural repair (2022).
Leading Organisations in the COPD Patent Dataset
Patent activity is clearly dominated by large biopharmaceutical companies, with academic institutions contributing primarily to diagnostics and novel mechanistic hypotheses.
| Organisation | Primary Focus | Jurisdictions | Filing Period | Stage Signal |
|---|---|---|---|---|
| Regeneron / Sanofi Biotechnology | Anti-IL-33 & anti-IL-4R antibodies | WO, US, AU, IL, TW, KR, BR, JP, NZ | 2019–2025 | Phase III |
| MedImmune Limited (AstraZeneca) | Tozorakimab (MEDI3506) anti-IL-33 | WO, CA, AU, US, JP, TW, BR | 2022–2025 | Phase III |
| AstraZeneca AB | Benralizumab (anti-IL-5Rα) in COPD | JP (multiple) | 2016–2025 | Phase III |
| Genentech, Inc. | ST2 antagonist, virus-triggered exacerbations | JP, CN | 2024 | Phase IIb |
| Boehringer Ingelheim Pharma | PDE4i + tiotropium combinations | ES, JP | 2004–2007 | Foundational IP |
Track COPD assignee filing strategies across jurisdictions
Monitor IP build-out, identify white spaces, and benchmark competitor programs with PatSnap Analytics.
From Patent Filings to Clinical Evidence
Retrieved results contain the following signals of clinical translation, ranging from Phase III study references to precise dose regimen specifications indicating post-Phase II dose selection.
Tozorakimab Phase III (NCT05166889)
A retrieved filing from MedImmune Limited (WO, 2025) explicitly references a Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of tozorakimab in Participants with Symptomatic COPD with a History of COPD Exacerbations (NCT05166889). Precise dose regimens (300–600 mg Q4W or Q8W) in retrieved filings suggest post-Phase II dose selection has occurred.
NCT05166889 · WO filing 2025Genentech ST2 Antagonist Phase IIb Study
A retrieved CN filing from Genentech describes a Phase IIb, randomized, double-blind, placebo-controlled, multicenter study enrolling approximately 930 COPD patients (current or ex-smokers with frequent exacerbations) evaluating an ST2 antagonist (described as atelizumab) vs. SOC. Stratification by smoking status and region is specified. The compound is linked to up to 45% reduction in annualized exacerbation rates vs. standard of care.
Phase IIb · Atelizumab · 476 mg Day 1Benralizumab Enriched Population Criteria
Retrieved filings specify enrollment criteria consistent with late-stage clinical protocol design: blood eosinophil count ≥300/µL, ≥2 prior exacerbations per year, and patients on triple background therapy (ICS + LABA + LAMA). This highly enriched patient selection strategy represents the most specific biomarker-linked enrollment criteria in this dataset, reflecting the broader movement toward precision medicine in respiratory biologics.
≥300 eos/µL · ≥2 exacerbations/yr · Triple therapyTriple Therapy Gap: 30–40% Remain Uncontrolled
The retrieved MedImmune WO filing notes that even maximal triple therapy (ICS + LABA + LAMA) leaves 30–40% of patients with moderate-to-severe exacerbations, establishing the clinical rationale for biologic add-on. AstraZeneca benralizumab filings specify that biologic add-on is deployed on top of triple therapy, formalizing the concept that biologics will complement rather than replace inhaled maintenance therapy. Multiple filings reference FEV1/FVC and FEV1% predicted as primary outcome measures, consistent with standard COPD trial design per EMA guidance.
30–40% uncontrolled on triple therapyCOPD Drug Pipeline — Key Questions Answered
The dominant molecular targets in the COPD patent and literature landscape are cytokines and their receptors—particularly the IL-33/ST2 axis, the IL-4/IL-13 shared receptor IL-4R, IL-5 receptor alpha (IL-5Rα), and IL-1R1—alongside structural and enzymatic targets including phosphodiesterase 4 (PDE4), muscarinic M3 receptors, matrix metalloproteinases (MMPs), and the chemokine receptor CXCR2.
The strongest Phase III clinical signal in this dataset is tozorakimab (MEDI3506), an anti-IL-33 antibody developed by MedImmune Limited (an AstraZeneca subsidiary). A retrieved filing explicitly references a Phase III, multicentre, randomised, double-blind, chronic-dosing, parallel-group, placebo-controlled study evaluating tozorakimab in COPD patients with a history of exacerbations (NCT05166889).
IL-33 is an epithelial alarmin released upon airway injury (including viral infection) that activates ST2 (also called IL1RL1) on innate lymphoid cells, mast cells, and eosinophils to amplify type 2 inflammation. Genentech filings uniquely position ST2 antagonism as a mechanism for attenuating virus-triggered inflammatory cascades without impairing antiviral host defense—directly linking the antiviral trigger dimension to the biologic modality dimension.
AstraZeneca filings for benralizumab (anti-IL-5Rα) in COPD specify enrollment criteria of blood eosinophil count ≥300/µL, ≥2 prior exacerbations per year, and patients already on triple background therapy (ICS + LABA + LAMA). This represents a precision medicine approach using biomarker-enriched populations.
Beyond bronchodilators, small-molecule approaches in this dataset include PDE4 inhibitors from Pfizer, GlaxoSmithKline, Boehringer Ingelheim, Chiesi, and Gilead; p38 MAPK inhibitors from Mereo BioPharma targeting overproduction of IL-1, IL-6, IL-8, and TNF-α; prostacyclin analogues combined with leukotriene inhibitors from ReversPAH LLC for steroid-unresponsive COPD; and LXR agonists and miR-33 antagonists proposed by Columbia University for emphysema repair.
Emerging epithelial repair approaches include: epigenetic co-delivery systems using liposome/biodegradable polymer carriers co-delivering antioxidants and plasmid DNA encoding epigenetic regulatory enzymes (Tokyo Metropolitan University); curcuminoid compositions enriched in bisdemethoxycurcumin (≥20% w/w) for regenerating damaged alveolar cells (Sami-Sabinsa Group Limited); type V collagen tolerization (Indiana University); and LXR agonists with miR-33 antagonism for cholesterol metabolism modulation and innate immune pathway dampening (Columbia University).
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About COPDAccelerate Your COPD Drug Discovery Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map the COPD pipeline, identify white spaces, and monitor clinical-stage signals across 2B+ patent and literature records.
References
- Methods for treating COPD by administering an IL-33 antagonist — Regeneron Pharmaceuticals, Inc., 2021 [Patent, WO]
- Treatment of Chronic Obstructive Pulmonary Disease With An Anti-Interleukin-33 Antibody — MedImmune Limited, 2025 [Patent, US]
- Treatment of chronic obstructive pulmonary disease with anti-interleukin-33 antibodies — MedImmune Limited, 2024 [Patent, JP]
- Methods for treating COPD by administering an IL-4R antagonist — Regeneron Pharmaceuticals, Inc., 2024 [Patent, WO]
- Methods for treating COPD in enriched patient populations using benralizumab — AstraZeneca AB, 2025 [Patent, JP]
- Method for treating chronic obstructive pulmonary disease with ST2 antagonists — Genentech, Inc., 2024 [Patent, JP]
- Treatment of chronic obstructive pulmonary disease with Anti-TSLP antibody — MedImmune LLC, 2025 [Patent, TW]
- Compositions and methods for treating COPD exacerbation (anti-IL-1R1) — MedImmune Limited, 2011 [Patent, WO]
- CD20 binding molecules for the treatment of COPD — Baadsgaard, Ole / Genmab A/S, 2008 [Patent, WO]
- Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes — Pfizer Products Inc., 2002 [Patent, EP]
- Heteroaryl derivatives for the treatment of respiratory diseases (dual PDE4/M3) — Chiesi Farmaceutici S.P.A., 2018 [Patent, ES]
- Combination of a PDE4 inhibitor and tiotropium to treat obstructive airways diseases — Boehringer Ingelheim Pharma GmbH & Co. KG, 2007 [Patent, ES]
- "All I want for Christmas is Two": Novel Fixed-Combination Inhalers for COPD and Outlook for 2014 — Beeh, Insaf Respiratory Research Institute, 2013 [Paper]
- Methods and compositions for treating COPD, asthma, pulmonary hypertension (prostacyclin + leukotriene) — ReversPAH LLC, 2022 [Patent, US]
- Dosing regimens for the treatment of acute exacerbations of COPD (p38 MAPK inhibitor) — Mereo BioPharma 1 Limited, 2019 [Patent, JP]
- COPD treatment with epigenetic control carrier having antioxidative function — Tokyo Metropolitan University, 2016 [Patent, JP]
- Composition for managing chronic obstructive pulmonary disease (curcuminoid) — Sami-Sabinsa Group Limited, 2022 [Patent, CN]
- Compositions and methods for treating COPD and asthma (type V collagen) — Indiana University Research and Technology Corporation, 2012 [Patent, JP]
- Liver X receptor agonists in the treatment of emphysema — D'Armiento, Jeanine (Columbia University), 2016 [Patent, US]
- Long-term doxycycline and lung function in COPD: A pilot observation — Institute of Pulmocare and Research, Kolkata, 2014 [Paper]
- Methods and compositions for preventing or treating acute exacerbations with polyclonal immunoglobulin — CSL Behring AG, 2024 [Patent, JP]
- CXCR2 binding polypeptide (neutrophil recruitment in COPD) — Novartis AG, 2013 [Patent, JP]
- Chronic Obstructive Pulmonary Disease, Neutrophils and Bacterial Infection: IL-17 and IL-22 — University of Manchester, 2015 [Paper]
- Methods for treatment of COPD and/or therapy monitoring (M-CSF biomarker) — Harvard University, 2016 [Patent, WO]
- Methods for treating exacerbations of inflammatory respiratory diseases (LPA biomarkers) — F. Hoffmann-La Roche AG, 2024 [Patent, JP]
- Methods of diagnosing COPD using novel molecular biomarkers (DMBT1, KIAA1199) — Medical University of Vienna / Transgenion GmbH, 2015 [Patent, WO]
- ActRII proteins and uses thereof (pulmonary hypertension associated with COPD) — Acceleron Pharma Inc., 2024 [Patent, JP]
- World Health Organization — COPD Fact Sheet
- GOLD — Global Initiative for Chronic Obstructive Lung Disease Guidelines
- European Medicines Agency — COPD Guideline on Clinical Investigation
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only. It should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.